Novel blood biomarkers for Alzheimer’s disease – ready for clinical use?

Alzheimer’s disease (AD) is the most common neurodegenerative disease, with progressive amnestic symptoms being the most common presentation at clinical onset. It is expected that roughly 50 million individuals suffer from the disease worldwide, making it a significant global health challenge. Since its conception in 1907 by the German neuropathologist Alois Alzheimer, it is now well known that the disease has a preclinical phase of 10-20 years before symptom onset, involving extracellular cortical deposition of β-amyloid (“Aβ plaques”, “A”) and a subsequent deposition of hyperphosphorylated tau (tau tangles, “T”) into intracellular aggregates, which – together with a progressive loss of neurons (neurodegeneration, “N”) – constitute the hallmarks of the disease.

Det här är ett utplock av en intressant artikel från KBN – Nr. 2 – vol. 36 – 2024.